Yutaka Niihara
Chief Executive Officer at EMI Holding, Inc.
Net worth: 1 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Willis Lee | M | 64 |
Emmaus Medical, Inc.
 Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA.
Newfield Nutrition Corp.
EMI Holding, Inc.
 EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | 21 years |
| Lan T. Tran | F | 48 |
Emmaus Medical, Inc.
Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA.
Emmaus Medical Europe Ltd.
Newfield Nutrition Corp.
| 16 years |
| Ian Zwicker | M | 77 | 5 years | |
| Yasushi Nagasaki | M | 57 |
Newfield Nutrition Corp.
EMI Holding, Inc.
EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | 13 years |
| Seah LIm | M | 66 | 2 years | |
| Soomi Niihara | F | - |
Hope International Hospice, Inc.
 Hope International Hospice, Inc. Hospital/Nursing ManagementHealth Services Hope International Hospice, Inc. provides services across language-ethnic patient groups, residing within the geographical boundaries of Los Angeles County and parts of Orange County. Its services include medical expertise, nursing care personal care of bathing, grooming and activities of daily living. The company is headquartered in Torrance, CA. | - |
| Wei Peu Zen | M | 71 | 5 years | |
| Ian A. Cook | M | 64 |
David Geffen School of Medicine
| 14 years |
| Charles Stark | M | 68 |
EMI Holding, Inc.
EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | 11 years |
| Perry Shieh | M | - |
David Geffen School of Medicine
| - |
| Richard David | M | 64 |
David Geffen School of Medicine
| - |
| Chun Kit Ho | M | 47 |
David Geffen School of Medicine
| - |
| Cathleen Bairey-Merz | M | 68 |
David Geffen School of Medicine
| - |
| Jonathan Corren | M | - |
David Geffen School of Medicine
| - |
| George Sekulich | M | 59 |
EMI Holding, Inc.
EMI Holding, Inc. Pharmaceuticals: MajorHealth Technology EMI Holding, Inc. discovers, develops, and commercializes treatments and therapies for rare diseases. The firm also engages in the marketing and sale of NutreStore L-glutamine powder for oral solution, a treatment for short bowel syndrome and the sale of L-glutamine as a nutritional supplement under the brand name AminoPure. The company was founded by Yutaka Niihara in 1987 and is headquartered in Torrance, CA. | 10 years |
| Heather Dale Jones | M | - |
David Geffen School of Medicine
| - |
| Andrew Woo | M | 61 |
David Geffen School of Medicine
| - |
| Linda Liau | M | 57 |
David Geffen School of Medicine
| - |
| Matthew Freeby | M | - |
David Geffen School of Medicine
| - |
| Dennis Joseph Slamon | M | 75 |
David Geffen School of Medicine
| - |
| Linda M. Rosenstock | M | 73 |
David Geffen School of Medicine
| 24 years |
| Jason Terrell | M | 43 | 7 years | |
| Frederick C. Beddingfield | M | 59 |
David Geffen School of Medicine
| 21 years |
| Arie Belldegrun | M | 74 |
David Geffen School of Medicine
| 24 years |
| Robert E. Reiter | M | - |
David Geffen School of Medicine
| - |
| David L. Hill | M | 73 |
David Geffen School of Medicine
| - |
| Owen Witte | M | 74 |
David Geffen School of Medicine
| - |
| Peter Ludlum | M | 68 |
Newfield Nutrition Corp.
| - |
| Robert Figlin | M | - |
David Geffen School of Medicine
| - |
| Jeffery F. Miller | M | - |
David Geffen School of Medicine
| - |
| Scott Weingarten | M | - |
David Geffen School of Medicine
| - |
| Julia Gouw | F | 64 |
David Geffen School of Medicine
| - |
| Henry McKinnell | M | 81 |
Emmaus Medical, Inc.
Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA. | 14 years |
| Allen Nissenson | M | 77 |
David Geffen School of Medicine
| 47 years |
| Anna M. Wu | M | - |
David Geffen School of Medicine
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jane Pine Wood | F | 62 | 2 years | |
| Robert Dickey | M | 68 | 3 years | |
| Masaharu Osato | M | 70 | 3 years | |
| William Emmerson | M | - |
Loma Linda University
| 5 years |
| Robin Smith | M | 59 | - | |
| Otis Maynard | M | - |
Loma Linda University
| 4 years |
| Lori Teranishi | F | - | - | |
| Ming Lai Yeung | M | 75 |
Loma Linda University
| 1 years |
| John A. Sackett | M | - |
Loma Linda University
| 1 years |
| Donald R. Hall | M | - |
Loma Linda University
| 3 years |
| Floyd Petersen | M | 80 |
Loma Linda University School of Medicine
| 28 years |
| Walid A. Shinnawi | M | - |
Loma Linda University
| 4 years |
| Joseph C. Sherwood | M | 69 | 1 years | |
| Douglas W. Wilmore | M | 85 |
Emmaus Medical, Inc.
Emmaus Medical, Inc. BiotechnologyHealth Technology Emmaus Medical, Inc. engages in the discovery, development and commercialization of treatments and therapies for rare diseases. Its current business is the late-stage development presently in Phase III clinical trials with the FDA of the amino acid L-glutamine as a prescription drug for the treatment of Sickle Cell Disease. The company was founded on December 20, 2000 and is headquartered in Torrance, CA. | - |
| Alfred F. Lui | M | - | 1 years | |
| Hugh A. Neuharth | M | - |
Loma Linda University
| 4 years |
| Stephen Tracey | M | - |
Loma Linda University
| 4 years |
| WALKER JAN | F | - |
Loma Linda University
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 53 | 100.00% |
| United Kingdom | 1 | 1.89% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Yutaka Niihara
- Personal Network
